Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Szilard Vasas

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
JAMA Network Open|May 22, 2023
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical TrialAditi R Saxena, Juan P Frias, Lisa S Brown, et al.
The New England Journal of Medicine|May 28, 2024
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed HyperlipidemiaChristie M Ballantyne, Szilard Vasas, Masoud Azizad, et al.
Diabetes, Obesity & Metabolism|October 17, 2024
Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled studyNeeta B Amin, Robert Frederich, Nikolaos Tsamandouras, et al.
American Journal of Preventive Cardiology|June 15, 2026
Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR TrialsChristie M Ballantyne, Alexis Baass, Robert S Rosenson, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
JAMA Network Open|May 22, 2023
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical TrialAditi R Saxena, Juan P Frias, Lisa S Brown, et al.
The New England Journal of Medicine|May 28, 2024
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed HyperlipidemiaChristie M Ballantyne, Szilard Vasas, Masoud Azizad, et al.
Diabetes, Obesity & Metabolism|October 17, 2024
Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled studyNeeta B Amin, Robert Frederich, Nikolaos Tsamandouras, et al.
American Journal of Preventive Cardiology|June 15, 2026
Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR TrialsChristie M Ballantyne, Alexis Baass, Robert S Rosenson, et al.
Pageof 1